Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 10, 2017
Reporting Period: Month of October 2017
This filing serves as a notice regarding the expiration of specific warrant series previously extended by the Lod District Court in Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate notice rather than a financial report.
Material Changes
No financial material changes are reported. The filing confirms the expiration of Series 10, 11, and 12 Warrants on October 31, 2017, following a court-approved extension of their term.
Guidance, Outlook, and Risks
Management Commentary: The company confirms that the warrants will expire on the specified date.
Risks/Contingencies: The filing notes the finality of the warrant expiration, implying no further extension is anticipated for these specific series.
Investor Verification Checklist
- Verify the expiration date of Series 10, 11, and 12 Warrants (October 31, 2017).
- Confirm the status of any remaining outstanding warrants not covered by this notice.
- Review the company's most recent Form 20-F for actual financial performance data, as this 6-K contains no financial statements.